Patents by Inventor Jonathan Bayldon Baell

Jonathan Bayldon Baell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anxiolytic compounds
    Patent number: 10954231
    Abstract: The present invention relates to chemical compounds of general formula (I): which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 23, 2021
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Method of treatment and compounds for use therein
    Patent number: 10328075
    Abstract: The present invention relates generally to a method of therapeutically or prophylactically treating ischaemia-induced myocardial tissue damage, in particular ischaemia-reperfusion-induced myocardial tissue damage. More particularly, the present invention relates to a method of reducing the extent of ischaemia-induced myocardial tissue damage in a mammal by selectively upregulating FPR1-mediated ERK signalling. The method of the present invention is useful, inter alia, in reducing the extent and/or severity of myocardial tissue damage associated with conditions characterized by myocardial ischaemia or myocardial ischaemia and reperfusion, such as acute myocardial infarction caused by atherosclerotic artery occlusion or blood clot-induced artery occlusion.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: June 25, 2019
    Assignees: Baker Heart and Diabetes Institute, Monash University
    Inventors: Rebecca Helen Ritchie, Cheng Xue Qin, Arthur Christopoulos, Patrick Michael Sexton, Jonathan Bayldon Baell
  • Anxiolytic compounds
    Patent number: 10233181
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 19, 2019
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Anxiolytic compounds
    Patent number: 9975892
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: May 22, 2018
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20180105524
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 19, 2018
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20180105523
    Abstract: The present invention relates to chemical compounds of general formula (I): which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 19, 2018
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • A Method Of Treatment And Compounds For Use Therein
    Publication number: 20180092917
    Abstract: The present invention relates generally to a method of therapeutically or prophylactically treating ischaemia-induced myocardial tissue damage, in particular ischaemia-reperfusion-induced myocardial tissue damage. More particularly, the present invention relates to a method of reducing the extent of ischaemia-induced myocardial tissue damage in a mammal by selectively upregulating FPR1-mediated ERK signalling. The method of the present invention is useful, inter alia, in reducing the extent and/or severity of myocardial tissue damage associated with conditions characterised by myocardial ischaemia or myocardial ischaemia and reperfusion, such as acute myocardial infarction caused by atherosclerotic artery occlusion or blood clot-induced artery occlusion.
    Type: Application
    Filed: February 4, 2016
    Publication date: April 5, 2018
    Inventors: Rebecca Helen Ritchie, Cheng Xue Qin, Arthur Christopoulos, Patrick Michael Sexton, Jonathan Bayldon Baell
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20170183347
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: January 4, 2017
    Publication date: June 29, 2017
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Anxiolytic compounds
    Patent number: 9573945
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: February 21, 2017
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Compounds and methods of use
    Patent number: 9067928
    Abstract: In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: June 30, 2015
    Assignees: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Jonathan Bayldon Baell, Chinh Thien Bui, Peter Colman, Danette A. Dudley, Wayne J. Fairbrother, John A. Flygare, Guillaume Laurent Lessene, Chudi Ndubaku, George Nikolakopoulos, Carl Steven Rye, Brad Edmund Sleebs, Brian John Smith, Keith Geoffrey Watson, Steven W. Elmore, Andrew M. Petros, Andrew J. Souers, Peter Czabotar
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20150166534
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: November 5, 2014
    Publication date: June 18, 2015
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Small-molecules as therapeutics
    Patent number: 9023848
    Abstract: The present invention provides compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: May 5, 2015
    Assignee: Bionomics Limited
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Damian Wojciech Grobelny, Sue O'Connor, Jonathan Bayldon Baell, Brad Sleebs, Ian Phillip Street
  • Protein kinase inhibitors and methods of treatment
    Patent number: 8962830
    Abstract: The present invention relates to chemical compounds of formula (I) and methods for their use and preparation. In particular, the invention relates to substituted pyrazolo[3,4-d]pyrimidine based compounds which can be used in treating proliferative disorders, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: February 24, 2015
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Guillaume Laurent Lessene, Jonathan Bayldon Baell, Antony Wilks Burgess, Hiroshi Maruta
  • Anxiolytic compounds
    Patent number: 8906912
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: December 9, 2014
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • NOVEL SMALL-MOLECULES AS THERAPEUTICS
    Publication number: 20140088104
    Abstract: The present invention provides compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression.
    Type: Application
    Filed: March 2, 2012
    Publication date: March 27, 2014
    Applicant: Bionomics Limited
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Damian Wojciech, Sue O'Connor, Jonathan Bayldon Baell, Brad Sleebs, Ian Phillip Street
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20140045839
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: September 18, 2013
    Publication date: February 13, 2014
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • COMPOUNDS AND METHODS OF USE
    Publication number: 20140005190
    Abstract: In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.
    Type: Application
    Filed: June 27, 2013
    Publication date: January 2, 2014
    Applicants: Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research, AbbVie Inc.
    Inventors: JONATHAN BAYLDON BAELL, CHINH THIEN BUI, PETER COLMAN, DANETTE A. DUDLEY, WAYNE J. FAIRBROTHER, JOHN A. FLYGARE, GUILLAUME LAURENT LESSENE, CHUDI NDUBAKU, GEORGE NIKOLAKOPOULOS, CARL STEVEN RYE, BRAD EDMUND SLEEBS, BRIAN JOHN SMITH, KEITH GEOFFREY WATSON, STEVEN W. ELMORE, ANDREW M. PETROS, ANDREW J. SOUERS, PETER CZABOTAR
  • Anxiolytic compounds
    Patent number: 8614212
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 24, 2013
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Anxiolytic compounds
    Patent number: 8551990
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 8, 2013
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Philip Street, Nurul Quazi, Chinh Thien Bui
  • Compounds and methods of use
    Patent number: 8518970
    Abstract: In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: August 27, 2013
    Assignees: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Jonathan Bayldon Baell, Chinh Thien Bui, Peter Colman, Danette A. Dudley, Wayne J. Fairbrother, John A. Flygare, Guillaume Laurent Lessene, Chudi Ndubaku, George Nikolakopoulos, Carl Steven Rye, Brad Edmund Sleebs, Brian John Smith, Keith Geoffrey Watson, Steven W. Elmore, Andrew M. Petros, Andrew J. Souers, Peter Czabotar